Navigation Links
diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
Date:9/29/2008

SOUTH SAN FRANCISCO, CALIF., Sept. 29 /PRNewswire/ -- diaDexus, Inc. today announced its partnership with the Living Heart Foundation (LHF), a non-profit organization dedicated to combating cardiovascular disease in current and retired NFL players. The PLAC(R) Test will be included as part of the LHF's cardiovascular risk assessment and disease prevention program designed to identify individuals at elevated risk for suffering a heart attack or stroke.

The PLAC Test is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. The PLAC Test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis that cause the majority of cardiac events. Clinical research demonstrates that early diagnosis of cardiovascular disease improves the likelihood of preventing these events.

"Traditional risk factors fail to identify many people at risk for developing cardiovascular disease," said Dr. Archie Roberts, founder of the Living Heart Foundation and a former NFL Quarterback. "We are pleased to offer the PLAC Test which provides new information, beyond traditional risk factors, to help identify those individuals with an increased chance of suffering from a cardiovascular event, allowing them to take the necessary steps to improve not only their health, but also their chance of survival."

Dr. Roberts created the LHF to encourage athletes to educate themselves on the importance of early detection and aggressive management of cardiovascular disease through free health clinics and events. The cardiovascular risk assessment and disease prevention programs held around the country will also contribute to research conducted by the LHF exploring the relationship between professional football players and cardiovascular disease.

"I'm thankful the LHF has incorporated the PLAC Test into their health program, as it was an eye opener for my overall health," said David O'Brien, former NFL player for the Minnesota Vikings, New York Giants and St. Louis Cardinals. "I never had heart problems, and my cholesterol was under control so I assumed I was not at risk for a heart attack or stroke. The PLAC Test identified my hidden risk for these events and enabled my doctors to prescribe an aggressive treatment program to lower my risk."

diaDexus is donating the PLAC Test kits for the LHF cardiovascular risk assessment and disease prevention program.

About diaDexus

diaDexus, Inc., a privately held diagnostics company based in South San Francisco, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. For more information, visit http://www.plactest.com or http://www.diaDexus.com.

About the Living Heart Foundation (LHF)

Living Heart Foundation (LHF) is a 501 (c) (3) entity with a national network of hospitals and physicians that unite to fight cardiovascular disease (CVD). The Foundation emphasizes CVD awareness, education, objective testing, early diagnosis and credible research. The 5-year-old ongoing NFL retired player screening/study has a database of over 1,400 former players.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touch Bionics acquires LIVINGSKIN
2. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
3. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
4. ATS Medical Expands Open Pivot Heart Valve Offerings
5. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
6. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
7. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
8. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
9. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
10. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
11. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):